title: Survival after coronary revascularization, with and without mitral valve surgery, in patients with ischemic mitral regurgitation.
abstract: BACKGROUND
  The most appropriate treatment for patients with ischemic mitral regurgitation (IMR) is often debated. We compared the survival rates of patients with IMR undergoing different treatment strategies, namely: medical therapy, percutaneous coronary intervention (PCI), coronary artery bypass grafting (CABG), and CABG + mitral valve (MV) surgery.
  
  
  RESULTS
  Patients undergoing catheterization between 1986 and 2001 were included. IMR was defined as: >or=grade 2+ mitral regurgitation (MR) and significant coronary artery disease (CAD) without primary mitral valve disease. Patients undergoing catheterization for the evaluation of congenital or other valvular heart disease were excluded. Multivariable Cox proportional hazards modeling was utilized to assess the independent relation between treatment and survival. Propensity score methods were used to correct for the nonrandom assignment of treatment. Of the 2,757 patients who met study criteria: 1,305 were treated medically, 537 underwent PCI, 687 underwent CABG, and 228 underwent CABG + MV surgery. The median duration of follow-up was 3.2 (0.9, 7.1) years. Patients undergoing CABG + MV surgery had more severe MR and more severe heart failure than those treated by other modalities. After adjusting for differences in baseline characteristics, patients undergoing PCI, CABG, and CABG + MV surgery had a 31% (hazards ratio [HR]=0.69; P=0.0001), 42% (HR=0.58; P=0.0001), and 42% (HR=0.58; P=0.0001) reduction in the risk of death, respectively, compared with those undergoing medical therapy. The performance of mitral valve surgery with CABG was not associated with improved survival versus CABG alone (P=0.258).
  
  
  CONCLUSIONS
  Among patients with IMR, treatment with PCI, CABG, or CABG + MV surgery is associated with improved survival compared with medical therapy.
authors.affiliation: Duke Clinical Research Institute, Duke University Medical Center, Durham, NC, USA. trich001@mc.duke.edu
authors.forename: Benjamin H
authors.initials: BH
authors.lastname: Trichon
authors.forename: Donald D
authors.initials: DD
authors.lastname: Glower
authors.forename: Linda K
authors.initials: LK
authors.lastname: Shaw
authors.forename: Christopher H
authors.initials: CH
authors.lastname: Cabell
authors.forename: Kevin J
authors.initials: KJ
authors.lastname: Anstrom
authors.forename: G Michael
authors.initials: GM
authors.lastname: Felker
authors.forename: Christopher M
authors.initials: CM
authors.lastname: O'Connor
mesh_terms: D000368:Aged; D015906:Angioplasty, Balloon, Coronary; D001026:Coronary Artery Bypass; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D008943:Mitral Valve / Q000601:surgery*; D008944:Mitral Valve Insufficiency / Q000175:diagnosis / Q000401:mortality* / Q000601:surgery / Q000628:therapy*; D017202:Myocardial Ischemia / Q000401:mortality / Q000601:surgery / Q000628:therapy; D016019:Survival Analysis; D015996:Survival Rate